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ABSTRACT
Introduction: At present, physicians have a limited
ability to predict major cardiovascular complications
after non-cardiac surgery and little is known about the
anatomy of coronary arteries associated with
perioperative myocardial infarction. We have initiated
the Coronary CT Angiography (CTA) VISION Study to
(1) establish the predictive value of coronary CTA for
perioperative myocardial infarction and death and
(2) describe the coronary anatomy of patients that
have a perioperative myocardial infarction.
Methods and analysis: The Coronary CTAVISION
Study is prospective observational study. Preoperative
coronary CTA will be performed in 1000–1500 patients
with a history of vascular disease or at least three
cardiovascular risk factors who are undergoing major
elective non-cardiac surgery. Serial troponin will be
measured 6–12 h after surgery and daily for the first
3 days after surgery. Major vascular outcomes at 30 days
and 1 year after surgery will be independently adjudicated.
Ethics and dissemination: Coronary CTA results in a
measurable radiation exposure that is similar to a nuclear
perfusion scan (10–12 mSV). Treating physicians will be
blinded to the CTA results until 30 days after surgery in
order to provide the most unbiased assessment of its
prognostic capabilities. The only exception will be the
presence of a left main stenosis >50%. This approach is
supported by best available current evidence that,
excluding left main disease, prophylatic revascularisation
prior to non-cardiac surgery does not improve outcomes.
An external safety and monitoring committee is
overseeing the study and will review outcome data at
regular intervals. Publications describing the results of the
study will be submitted to major peer-reviewed journals
and presented at international medical conferences.
INTRODUCTION
Globally over 200 million patients undergo
major non-cardiac surgery annually. Despite
the beneﬁts of surgery, annually over 5 million
non-cardiac surgery patients will suffer a car-
diovascular death or non-fatal myocardial
infarction in the ﬁrst 30 days after surgery.1
Limited capacity to predict major perioperative
ischemic events
Accurate risk estimation is important to
allow patients and physicians to make
informed choices about the appropriate-
ness of surgery and to inform perioperative
management (eg, anaesthetic approach).
Risk prediction based on clinical risk
factors and functional capacity is subopti-
mal.2 This is probably because many
patients are inactive for substantial periods
of time prior to their non-cardiac surgery
(eg, orthopaedic, vascular and oncology
ARTICLE SUMMARY
Article focus
This study protocol has two primary objectives.
▪ To establish the predictive value of coronary CT
angiography for perioperative myocardial infarc-
tion and death.
▪ To describe the preoperative coronary anatomy of
patients that have a perioperative myocardial
infarction.
Key messages
▪ Coronary CT angiography may be a valuable tool
for risk stratification prior to non-cardiac surgery
but needs to be evaluated in a prospective study.
Strengths and limitations of this study
▪ Large multicentre blinded imaging study with
independent adjudication of clinical outcomes.
▪ Recruitment targeted to a population at intermedi-
ate to high risk of peri-operative ischaemia.
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patients) due to their underlying surgical condition,
and as such, many patients with substantial coronary
artery disease (CAD) may not have experienced any
suggestive symptoms.
In an attempt to improve preoperative risk predic-
tion, some patients undergo non-invasive cardiac
stress tests (eg, stress echocardiography and nuclear
scintigraphy imaging) prior to non-cardiac surgery.3
A recent meta-analyses evaluating these two tests
demonstrated, however, that they have only moderate
negative likelihood ratios (stress echocardiography
0.23 and stress perfusion imaging 0.44), and that
more than a third of the patients who suffered a
major perioperative cardiovascular event had a nega-
tive preoperative test result.4 These data represent
likely a best-case scenario because most of the studies
have not assessed whether these non-invasive cardiac
stress tests provide independent prognostic informa-
tion beyond known clinical variables. The few studies
that have undertaken multivariable regression analysis
provide unreliable estimates because they did not
include all the known independent clinical variables
or the analysis had too few events for the number of
variables assessed.5–9
Mechanisms of perioperative ischemic events
Although perioperative myocardial infarction is the most
common major perioperative cardiac complication, little
is known about its pathophysiology.3 Understanding the
pathophysiology of perioperative myocardial infarction is
important to help inform which potential prophylactic
interventions and acute management interventions
should be evaluated in randomised controlled trials to
improve the outcome of patients undergoing non-
cardiac surgery.
A commonly proposed mechanism of perioperative
myocardial infarction relates to myocardial oxygen
supply demand mismatch. Fluid shifts, catecholamine
surges, hypotension, anaemia and hypoxia can occur
during and after major non-cardiac surgery and transi-
ently increase myocardial oxygen demand.3 In coronary
vessels with high grade stenoses or occlusions, the
supply response may be limited, resulting in supply-
demand mismatch myocardial ischaemia or infarction.
An additional or alternative mechanism of perioperative
myocardial infarction is that the acute stress of surgery
and mechanical tissue injury induces a hypercoagulable
state that increases the risk of coronary thrombus for-
mation at the site of a ﬁssured plaque or with low cor-
onary ﬂow.
Rationale for use of coronary CTA prior to
non-cardiac surgery
Coronary CTA may have several advantages for risk
stratiﬁcation prior to non-cardiac surgery. First, coron-
ary CTA does not require exercise or pharmacological
stress to detect CAD and therefore is well suited to the
vascular and orthopaedic surgical populations who
often cannot exercise or take the necessary pharmaco-
logical agents (eg, patients with asthma). Second, cor-
onary CTA can exclude obstructive CAD very reliably
as it has a high sensitivity for the detection of coron-
ary stenosis.10–13
Third, coronary CTA is a very sensitive modality for
the detection of high-risk coronary anatomy (left main
disease or three or two vessel disease including the prox-
imal left anterior descending (LAD) artery) as coronary
CTA can visualise these large proximal vessels very
well.13 Fourth, coronary CTA is the only non-invasive
modality that can detect non-obstructive atheroscler-
osis,14 and some of our research (eg, POISE)15 offers
clues that non-obstructive CAD may be responsible for a
substantial proportion of the perioperative myocardial
infarctions that occur in the non-cardiac surgery setting
through plaque rupture and thrombosis.
Finally, coronary CTA can provide a comprehensive
anatomic characterisation of the coronary arteries
prior to surgery, and this has substantial potential to
shed important insight into the extent of preoperative
coronary atherosclerosis in culprit vessels that are
associated with perioperative myocardial infarction.
OBJECTIVES OF THE CORONARY CTA VISION STUDY
The Coronary CTAVISION Study is a prospective cohort
study that will examine patients with, or at risk of, ath-
erosclerotic disease who are undergoing non-cardiac
surgery in order to determine: if preoperative coronary
CTA has additional predictive value, beyond clinical vari-
ables, for the occurrence of major perioperative cardiac
events (ie, cardiovascular death and non-fatal myocardial
infarction) at 30 days after surgery; and the underlying
coronary anatomy associated with perioperative myocar-
dial infarction. The Coronary CTA VISION Study is a
substudy of the VISION Study. The Vascular events In
non-cardiac Surgery patients cOhort evaluatioN
(VISION) Study is a 40 000 patient international pro-
spective cohort study that we are currently undertaking,
and this study is evaluating perioperative vascular com-
plications in patients undergoing non-cardiac surgery.
METHODS
Study design
The Coronary CTAVISION Study is a prospective obser-
vational study of coronary CTA performed in patients
prior to non-cardiac surgery.
Study population
The investigators will consider all patients undergoing
elective non-cardiac surgery for enrolment. Boxes 1
and 2 present the study’s inclusion and exclusion
criteria.
Clinical data collection
After obtaining written informed consent, research per-
sonnel will interview and examine patients and review
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their charts to obtain information on patient characteris-
tics that we are evaluating in the VISION Study to deter-
mine if they have potential independent predictors of
major perioperative vascular events. These variables
include risk factors, co-morbidities, medications, anaes-
thetic and surgical variables.
CTA imaging protocol
Once a patient is consented for the study, research
personnel coordinate an appointment for the patient’s
preoperative coronary CTA scan. Personnel in the radi-
ology department see patients prior to the coronary
CTA scan and, when necessary, pretreat the patients with
β-blockers (to achieve heart rate of 60 or less) and nitro-
glycerin (at a dose of 0.6–0.8 mg administered sublin-
gually) to optimise image quality. At centres with single
source scanners, patients who continue to have a heart
rate 70 bpm or greater despite β-blockade are excluded
from the study (90 bpm or greater with dual source
scanners). In patients with asthma, personnel use a
calcium channel blocker (diltazem 30–120 mg) is used
to achieve heart rate control. A non-contrast scan is
performed ﬁrst. This scan is prospectively triggered at
75% of the R to R (RR) interval, with 0.4–0.625 slice
thickness (depending on scanner type) and 3 mm incre-
ments. Technicians next perform a contrast scan and
inject contrast agent at a rate of 5.5–7 ml/s depending
on body habitus of the patient being scanned. For an
average patient, the dose of contrast is expected to be
approximately 80 ml. The contrast scan is retrospectively
gated or prospectively triggered with 0.4–0.625 slice
thickness (depending on scanner type). On scanners
with the capacity for prospective triggering, studies are
acquired with this technique whenever heart rate is
adequately controlled (HR<65) and regular. For retro-
spective acquisitions, dose modulation is used to minim-
ise radiation dose.
Standard initial reconstruction of the coronary CTA
data set is performed at 75% of the RR interval, with
additional reconstructions performed as required for
image interpretation. When retrospective gating is used,
reconstructions for functional assessment are performed
in 10 phases with 10% increments.
Participating sites
Participating centres have a 64 detector multidetector com-
puted tomography (MDCT) or greater with the capacity to
perform cardiac CT, an expert reader in cardiology or radi-
ology (as deﬁned by American Heart Association (AHA)/
American College of Cardiology (ACC) training standards
or their international equivalent) and a strong collabor-
ation between the imaging team and the clinical peri-
operative medicine service to facilitate patient recruitment.
The participating sites are listed in the appendix. Each
participating site submits several scans to conﬁrm adher-
ence to the study imaging protocol and achievement of
adequate image quality prior to the initiation of study
recruitment.
Box 1 Inclusion criteria
▸ All patients undergoing elective non-cardiac surgery are
eligible if
▸ They are ≥45 years of age.
▸ They require at least an overnight hospital admission after
surgery.
▸ They are undergoing one of the following surgeries
– Orthopaedic (major joint arthroplasty)
– Vascular
– Thoracic surgery (pneumonectomy, lobectomy, other
thoracic—wedge lung resection, mediastinal tumor resec-
tion, major chest wall resection)
– Major abdominal surgery (partial or total colectomy,
stomach surgery, visceral resection, cytoreductive surgery,
radial hysterectomy and radical prostatectomy)
– Major organ transplantation (kidney, liver, lung).
▸ They have enough time prior to non-cardiac surgery to obtain
a coronary CTA study.
▸ They fulfill one of the following additional criteria:
– History of coronary artery disease
– History of peripheral vascular disease
– History of stroke
– History of a physician diagnosis of congestive heart failure; OR
– Any three of the following six risk factors: (a) diabetes and
currently on an oral diabetic drug or insulin therapy, (b)
age ≥70 years, (c) history of smoking within 2 years of
surgery, (d) history of treatment for hypercholesterolemia,
(e) history of a transient ischaemic attack or (f ) a history of
hypertension.
Box 2 Exclusion criteria of the CTA VISION Study
All patients are excluded if
▸ They are referred to invasive coronary angiography prior to
non-cardiac surgery (coronary CTA will not provide informa-
tion incremental to an invasive angiogram).
▸ They have had a prior percutaneous coronary intervention with
stent implantation (due to limited ability of coronary CTA to
evaluate stents).
▸ They have a creatinine clearance <35 ml/min (to avoid risk of
contrast nephrotoxicity in patients potentially at risk).
▸ They have a known contrast reaction.
▸ They are pregnant.
▸ They have persistent atrial fibrillation or >2 atrial or ventricular
premature beats on a preoperative 12 lead ECG (suboptimal
image quality results from irregular heart rhythms at cardiac
CT due to difficulties with retrospective gating).
▸ They weight >300 lbs (obese patients have suboptimal image
quality due to a poor contrast to noise ratio).
▸ They have an inability to achieve the required heart rate prior
to coronary CTA despite medication (ie, a β-blocker or calcium
channel blocker) if the patient will be scanned on a single
source scanner they require a heart rate <70 bpm or a heart
rate <90 bpm if the patient will be scanned on a dual source
scanner.
▸ Patients who do not undergo non-cardiac surgery within
6 months of their coronary CTA.
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CTA interpretation and blinding
Coronary CTA is read by an expert radiologist or cardi-
ologist. These individuals read each coronary CTA exam
without knowledge of the clinical data. They report ﬁnd-
ings for each vessel, in terms of nature of plaque and
extent of narrowing, and they determine whether each
of the following four ﬁndings are present on the coron-
ary CTA: (1) normal—no evidence of coronary athero-
sclerotic plaque (this excludes subsequent ﬁndings),
(2) non-obstructive CAD—evidence of at least one cor-
onary artery plaque with a <50% stenosis, (3) obstructive
CAD—at least one coronary artery plaque with a ≥50%
stenosis, or (4) obstructive plaque with high-risk
anatomy (≥50% stenosis of the left main, ≥50% stenosis
in three coronary arteries, or ≥50% stenosis in two cor-
onary arteries including the proximal left anterior des-
cending (LAD) artery). Where calcium and/or motion
artefacts limit interpretability, the segments are identi-
ﬁed as non-evaluable and a forced interpretation on the
presence of stenosis is made. If there are more than
four non-evaluable segments, the scan is considered
non-diagnostic and excluded from the analysis.
The classiﬁcation of CTA ﬁndings being used in CTA
VISION predicts the risk of mortality over 1–2 years in
patients with stable CAD in the non-operative setting,16
similar to the results of the well-validated prognostic clas-
siﬁcation of invasive coronary angiography that puts
increased importance on the number of vessels with
≥50% stenoses, with particular emphasis on involvement
of the proximal LAD.17 Assessment of stenosis severity
into board categories (ie, 50–70% vs ≥70%) demon-
strates very good agreement between coronary CTA and
invasive angiography (κ=0.74).18 The reader calculates a
calcium score using the Agatston method using the non-
contrast scan.19 This score is recorded and is available
for subsequent analyses.
If a patient is discovered to have a ≥50% stenosis of
the left main we immediately provide this test result to
the patient’s physicians. All other patients have their
results withheld from the clinical care team until 30 days
after surgery.
Patient follow-up
After surgery, patients have a troponin measurement
drawn 6–12 h after surgery and on the ﬁrst, second and
third days after surgery. Standard orders ensure that
these tests are undertaken. Orders also ensure that an
ECG is undertaken immediately after an elevated tropo-
nin measurement is detected. Patients who are discov-
ered to have an elevated troponin with or without ECG
changes will usually undergo an echocardiogram or a
functional evaluation such as nuclear perfusion imaging
or stress MRI. Where clinically indicated, invasive coron-
ary angiography is performed.
Research personnel follow patients throughout their
time in hospital and personally evaluate patients and
review their medical records ensuring study orders have
been followed and noting any primary or secondary
outcomes. The research personnel contact patients by
phone at 30 days and 1 year postsurgery. If patients indi-
cate that they have experienced an outcome or hospital-
isation, the research personnel contact their physicians
to obtain the appropriate documentation.
Study outcomes
For our ﬁrst objective (ie, to determine if preoperative
coronary CTA has additional predictive value beyond
clinical variables) our primary outcome is a major
cardiac event (ie, a composite of cardiovascular death
and non-fatal myocardial infarction) at 30 days postsur-
gery. Individual secondary outcomes for our ﬁrst object-
ive at 1 year after surgery include cardiovascular death,
myocardial infarction and coronary revascularisation.
For our second objective (ie, to determine the under-
lying coronary anatomy associated with perioperative
myocardial infarction) our primary and only outcome is
myocardial infarction at 30 days after surgery.
The ﬁrst step in determining the underlying coronary
artery anatomy associated with a perioperative myocar-
dial infarction is to determine the region of the myocar-
dial infarction using a combination of clinical and
non-invasive tests. Two cardiologists blinded to the CTA
results will independently determine this using a pre-
speciﬁed algorithm based on literature and expert
opinion (table 1). After establishing this, we then look at
what the expert CTA evaluators stated was the under-
lying coronary artery anatomy (eg, <50% stenosis, 50–
69% stenosis and ≥70% stenosis) in the coronary artery
that supplied the region of the myocardial infarction.
Outcome adjudication
A committee of clinicians who are blinded to the CTA
results adjudicate the outcomes of death and myocardial
infarction. We will use the decisions from the
Adjudication Committee for all statistical analyses.
Sample size
Our sample size calculation is based on our primary
objective (ie, to determine if preoperative coronary CTA
has additional predictive value beyond clinical variables).
Of our two objectives, this objective requires the largest
number of patients to ensure the stability of the predic-
tion model. The VISION Study will determine the
optimal clinical risk prediction model, and we will then
undertake a multivariable analysis to determine if the
coronary CTA results have additional predictive value
beyond the VISION clinical risk prediction model.
Simulation studies demonstrate that logistic models
require 12–15 events per predictor to produce stable
estimates.20 21 We will evaluate four potential predictors
in our multivariable analysis: one VISION clinical risk
predication score and three types of coronary CTA
results (ie, non-obstructive CAD, obstructive CAD and
obstructive plaque with high-risk anatomy) with one ref-
erence category (normal). Given our eligibility criteria,
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we expect that the study participants will be evenly dis-
tributed across the four CTA result groups.
On the basis of the VISION Pilot Study and a previous
non-invasive cardiac testing study that we undertook in a
similar surgical population,22 we expect a 6% event rate
for major perioperative cardiac events in this study. table 2
presents the various sample sizes needed to test four
variables in a multivariable analysis based upon various
event rates and the required number of events per vari-
able. As the table indicates, if our event rate is 6% we
will need 1000 patients to achieve stable estimates. If our
event rate is 4%, we may need up to 1500 patients. We
are targeting a sample size of 1500 patients but this may
change depending on our event rate at 1000 patients.
Data analysis
To address our primary objective, we will undertake a
multivariable logistic regression analysis in which the
dependent variable is a major perioperative cardiac
event at 30 days after surgery and the independent
variables are the VISION clinical risk prediction score
and the four coronary CTA results discussed above. For
this logistic regression analysis we will use forced simul-
taneous entry (all candidate variables will remain in the
model) as opposed to automated stepwise selection,
because simulation studies have demonstrated a higher
risk of overﬁtting with the latter approach.23 24 To assess
the reliability of our models we will undertake bootstrap-
ping,25 because this technique is superior to cross-
validation and jack-knife techniques.26 We will test the
hypothesis that coronary CTA will have additional pre-
dictive value, beyond clinical variables, for the occur-
rence of major perioperative cardiac events in patients
undergoing non-cardiac surgery using the likelihood
ratio (LR) test: LR test=−2ln (L1/L2) where L1 and L2
are the likelihood for the reduced model with VISION
score alone, and likelihood for the full model with both
VISION score and CTA variables.27
For the logistic model we will report the ORs, 95%
CIs, and associated p values. For all tests, we will use
α=0.05 level of signiﬁcance. For all signiﬁcant associa-
tions we will report the likelihood ratio and the 95% CI.
Examination of residuals will provide an assessment of
model assumptions for regression analyses.
Goodness-of-ﬁt for the models will be performed using
appropriate Hosmer-Lemeshov tests. For the multivari-
able regression analysis, multicolinearity (correlations
among predictor variables) may exist.28 We will assess
colinearity using the variance inﬂation factor (VIF)
which measures the extent to which the variance of the
model coefﬁcients will be inﬂated (because of the cor-
relation of the variable with other predictor variables) if
that variable is included in the model. We will consider
variables with VIF >10 colinear and we will exclude one
of these variables from the analysis.29
Table 1 Diagnostic confidence in determination of culprit lesion in patients who fulfil our definition of myocardial infarction
Diagnostic confidence Criteria
Highly probable location of
lesion ▸ Thrombus or features of recent plaque rupture (irregular margins, hazy appearance and
dissection) coronary plaque fissure seen on invasive angiography or
▸ New area of infarction on cardiac MRI
Probable location of lesion
▸ New perfusion abnormality identified on SPECT testing
▸ New wall motion abnormality (as determined through comparison of preoperative and
postoperative echocardiography or MRI
▸ New wall motion abnormality as determined through comparison of preoperative CTA
myocardial function and postoperative echocardiography or
▸ New Q waves in two contiguous leads on the patients ECG
Possible location of lesion
▸ ST segment elevation (≥2 mm in leads V1, V2 or V3 OR ≥1 mm in the other leads) in two
contiguous leads
▸ ST segment depression (≥1 mm) in two contiguous leads
▸ Symmetric inversion of T waves ≥1 mm in at least two contiguous leads or
▸ Presumed new cardiac wall motion abnormality on echocardiography
▸ Presumed new fixed defect on SPECT testing
Table 2 Sample size needed to test four variables in a
multivariable analysis based upon various event rates and
the required number of events per variable
Required
number
of events
per variable
Number of
events
needed
Sample size needed to
test four variables in a
multivariable analysis
based on various event
rates
4% 6%
10 40 1000 667
12 48 1200 800
15 60 1500 1000
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For our secondary objective we will determine the pro-
portion of patients suffering a perioperative myocardial
infarction who on their coronary CTA the myocardial
infarction associated artery had a coronary artery sten-
osis of <50%, 50–69%, ≥70–99%, 100% or no coronary
artery stenosis and the associated 95% CIs. We will
perform all analyses using SAS version 9.2 (Cary, North
Carolina, USA).
Ethics
Coronary CTA results in a measurable radiation expos-
ure. Volume coverage of the whole heart using standard
acquisition parameters will approximately result in an
effective dose of 10–12 mSv if retrospectively gated CTA
is performed. The dose will likely be substantially lower
if prospectively triggered CTA is performed. The
maximum anticipated does is similar to a nuclear perfu-
sion scan (8–12 mSv), but greater than a standard chest
CT (5–7 mSv)30 and equals 3–4 years of the annual
average effective dose from background radiation
(3.6 mSv/year) or approximately 20% of the annual
whole body effective dose that is allowed for a radiation
worker (radiologist, radiological technologist; 50 mSv/
year).31
We feel that blinding of treating physicians to the cor-
onary CTA ﬁndings is important to provide the most
unbiased assessment of its prognostic capabilities. Thus,
in keeping with prior studies that evaluated non-invasive
tests in patients undergoing vascular surgery,5 32 the
attending surgeons and consultants in our study will not
know the results of the preoperative coronary CTA. The
best evidence currently available from the CARP Trial33
and DECREASE-V Trial34 suggests that there is no
beneﬁt to prophylactic coronary revascularisation prior
to non-cardiac surgery and therefore, the CTA results
are not required to guide treatment prior to non-cardiac
surgery. In the CARP Trial one-third of the patients had
three vessel CAD,33 and in the DECREASE-V Trial 67%
of the patients had three vessel CAD.34 The only excep-
tion is haemodynamically signiﬁcant left main disease
which was excluded in the CARP trial. Thus, if the cor-
onary CTA suggests signiﬁcant left main disease, the
results will be immediately disclosed to the treating phy-
sicians. For all patients in the study, the results of coron-
ary CTA will be provided to all family physicians,
internal medicine and cardiology consultants involved in
the care of the patients at 30 days postsurgery.
An external safety and monitoring committee (ESMC)
will convene early in the study and will meet again at
regular intervals. Interim analyses will be conducted
when approximately 25%, 50% and 75% of the expected
events have occurred and the data are available. The
analyses will be conducted on the total of adjudicated
and unadjudicated events at the appropriate time
points. If the ESMC decides that a deﬁnitive conclusion
has been reached for the overall study population or a
speciﬁc subgroup, they will immediately unblind the
Co-Principal Investigators and discuss the results
together.
CONCLUSION
Coronary CTA is a novel application of CT scanning with
potentially important clinical applications. This study
will evaluate the role of coronary CTA in risk stratiﬁca-
tion prior to non-cardiac surgery. If we demonstrate that
CTA has important additional predictive value beyond
clinical information in patients undergoing elective non-
cardiac surgery, this ﬁnding would allow this test to facili-
tate informed patient decision-making about the risks of
surgery and guide perioperative patient management.
This study will also provide insights into the underlying
coronary anatomy of coronary arteries that cause myo-
cardial infarction in the perioperative setting. This
knowledge will inform the selection of targeted preven-
tion and management interventions to evaluate in large
perioperative randomised controlled trials. Considering
that over 200 million adults undergo major non-cardiac
surgery annually and that we know little about how to
predict or manage major perioperative cardiac events,
highlights the importance of the Coronary CTA VISION
Study.
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